Literature DB >> 28220286

Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis.

Hyun Ah Choi1, Mi Ji Lee1, Chin-Sang Chung2.   

Abstract

Hypertrophic pachymeningitis (HP) is an important neurologic complication of granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis). The aim of this study is to investigate the clinical features, radiological findings, and diagnostic pitfalls of GPA-related HP. A retrospective chart review was performed to screen patients diagnosed with GPA at Samsung Medical Center between 1997 and 2016. Neurologic manifestation, laboratory findings, neuroimaging data, and clinical course were evaluated in all patients. Characteristics of patients with HP were compared to those of patients without HP. Sixty-five patients with GPA were identified. Twenty-five of these patients had central nervous system involvement. HP (N = 9, 36%) was the second most common radiologic finding. Other neurologic findings included stroke (N = 7, 28%) and granulomatous disease (N = 10, 40%). Patients with HP had lower incidences of systemic manifestations (N = 2, 22.2% vs. N = 38, 67.9%, p = 0.013 in the lung and N = 1, 11.1% vs. N = 28, 50.0%, p = 0.030 in the kidney) than those without HP. Six patients with GPA-related HP were MPO-ANCA positive (66.7%) and two had PR3-ANCA (22.2%). Most of the patients with HP presented with headache (N = 8, 88.9%) at a rate that is similar to those of primary headache disorders (migraine, tension-type, and stabbing) and other secondary headache disorders (postural type and meningitis). Patients with HP rarely had neurologic deficits (N = 3, 37.5%). Different clinical or radiologic features may be observed in GPA-related HP. Early recognition and accurate diagnosis of GPA-related HP are needed in addition to neuroimaging findings.

Entities:  

Keywords:  Antineutrophil cytoplasmic antibody (ANCA); Central nervous system (CNS); Cerebral vasculitis; Granulomatosis with polyangiitis (GPA); Hypertrophic pachymeningitis (HP); Neurologic manifestations; Wegener’s granulomatosis

Mesh:

Substances:

Year:  2017        PMID: 28220286     DOI: 10.1007/s00415-017-8416-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  Wegener granulomatosis: MR imaging findings in brain and meninges.

Authors:  J M Murphy; B Gomez-Anson; J H Gillard; N M Antoun; J Cross; J D Elliott; M Lockwood
Journal:  Radiology       Date:  1999-12       Impact factor: 11.105

Review 2.  The diagnosis of vasculitis.

Authors:  David Jayne
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-06       Impact factor: 4.098

3.  Wegener granulomatosis: CT and MR findings.

Authors:  J M Provenzale; N B Allen
Journal:  AJNR Am J Neuroradiol       Date:  1996-04       Impact factor: 3.825

Review 4.  ANCA small-vessel vasculitis.

Authors:  R J Falk; J C Jennette
Journal:  J Am Soc Nephrol       Date:  1997-02       Impact factor: 10.121

5.  Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature.

Authors:  E Reinhold-Keller; K de Groot; K Holl-Ulrich; A C Arlt; M Heller; A C Feller; W L Gross
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

6.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

Authors:  E Reinhold-Keller; N Beuge; U Latza; K de Groot; H Rudert; B Nölle; M Heller; W L Gross
Journal:  Arthritis Rheum       Date:  2000-05

7.  Wegener's granulomatosis with nervous system involvement: a hospital-based study.

Authors:  Yu-Hua Huang; Long-Sun Ro; Rong-Kuo Lyu; Hong-Shiu Chang; Yih-Ru Wu; Kuo-Hsuan Chang; Hung-Chou Kuo
Journal:  Eur Neurol       Date:  2015-03-10       Impact factor: 1.710

Review 8.  Idiopathic hypertrophic pachymeningitis.

Authors:  M J Kupersmith; V Martin; G Heller; A Shah; H J Mitnick
Journal:  Neurology       Date:  2004-03-09       Impact factor: 9.910

9.  Central nervous system involvement in Wegener granulomatosis.

Authors:  Raphaèle Seror; Alfred Mahr; Jacky Ramanoelina; Christian Pagnoux; Pascal Cohen; Loïc Guillevin
Journal:  Medicine (Baltimore)       Date:  2006-01       Impact factor: 1.889

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  10 in total

Review 1.  Pituitary involvement in patients with granulomatosis with polyangiitis: case series and literature review.

Authors:  Yu Gu; Xuefeng Sun; Min Peng; Ting Zhang; Juhong Shi; Jiangfeng Mao
Journal:  Rheumatol Int       Date:  2019-06-15       Impact factor: 2.631

Review 2.  Autoimmune diseases of the brain, imaging and clinical review.

Authors:  Ghazal Shadmani; Tyrell J Simkins; Reza Assadsangabi; Michelle Apperson; Lotfi Hacein-Bey; Osama Raslan; Vladimir Ivanovic
Journal:  Neuroradiol J       Date:  2021-09-07

3.  Granulomatosis with Polyangiitis Complicated by Hypertrophic Pachymeningitis Presenting with Simultaneous Multiple Intracerebral Hemorrhages.

Authors:  Eri Kato; Koichiro Tahara; Haeru Hayashi; Aki Shoji; Hiroaki Mori; Tetsuji Sawada
Journal:  Intern Med       Date:  2017-12-27       Impact factor: 1.271

4.  Combined Hypertrophic Pachymeningitis and Cerebral Venous Thrombosis in a Case of Granulomatosis with Polyangiitis.

Authors:  Tadahiro Kuribayashi; Yasuhiro Manabe; Shunya Fujiwara; Yoshio Omote; Hisashi Narai; Koji Abe
Journal:  Case Rep Neurol       Date:  2019-08-21

Review 5.  Central Nervous System Involvement in ANCA-Associated Vasculitis: What Neurologists Need to Know.

Authors:  Yang Zheng; Yinxi Zhang; Mengting Cai; Nanxi Lai; Zhong Chen; Meiping Ding
Journal:  Front Neurol       Date:  2019-01-10       Impact factor: 4.003

6.  Pituitary dysfunction in patients with ANCA associated vasculitis: prevalence, presentation, and outcomes.

Authors:  Chunjia Li; Yu Zou; Xin Lu; Guochun Wang; Xiaoming Shu
Journal:  Ther Adv Chronic Dis       Date:  2020-06-09       Impact factor: 5.091

7.  Propionibacterium acnes-associated chronic hypertrophic pachymeningitis followed by refractory otitis media: a case report.

Authors:  Eiichiro Amano; Keisuke Uchida; Tasuku Ishihara; Shinichi Otsu; Akira Machida; Yoshinobu Eishi
Journal:  BMC Neurol       Date:  2020-01-09       Impact factor: 2.474

8.  Hypertrophic spinal pachymeningitis caused by ANCA-associated vasculitis revealed by 18F-FDG PET/CT: A case report.

Authors:  Meiqi Wu; Jingyun Ren; Yaping Luo
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

9.  Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China.

Authors:  Suying Liu; Ling Guo; Xiaoyuan Fan; Zhaocui Zhang; Jiaxin Zhou; Xinping Tian; Mengtao Li; Xiaofeng Zeng; Li Wang; Fengchun Zhang
Journal:  Orphanet J Rare Dis       Date:  2021-03-31       Impact factor: 4.123

10.  Hypertrophic pachymeningitis in ANCA-associated vasculitis: a cross-sectional and multi-institutional study in Japan (J-CANVAS).

Authors:  Yasuhiro Shimojima; Dai Kishida; Takanori Ichikawa; Takashi Kida; Nobuyuki Yajima; Satoshi Omura; Daiki Nakagomi; Yoshiyuki Abe; Masatoshi Kadoya; Naoho Takizawa; Atsushi Nomura; Yuji Kukida; Naoya Kondo; Yasuhiko Yamano; Takuya Yanagida; Koji Endo; Shintaro Hirata; Kiyoshi Matsui; Tohru Takeuchi; Kunihiro Ichinose; Masaru Kato; Ryo Yanai; Yusuke Matsuo; Ryo Nishioka; Ryota Okazaki; Tomoaki Takata; Takafumi Ito; Mayuko Moriyama; Ayuko Takatani; Yoshia Miyawaki; Toshiko Ito-Ihara; Takashi Kawaguchi; Yutaka Kawahito; Yoshiki Sekijima
Journal:  Arthritis Res Ther       Date:  2022-08-23       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.